Tiroiditis Subakut

01Pathophysiology

Subacute thyroiditis is a self-limiting inflammatory disorder of the thyroid gland triggered by a preceding viral infection. The virus induces a cytotoxic immune response against thyroid follicular cells, leading to follicular disruption and unregulated release of preformed thyroid hormone (T3 and T4) into the bloodstream. This is not new hormone synthesis; it is a spillage phenomenon from damaged storage.

This mechanism directly explains the triphasic clinical course. In the first phase (thyrotoxic phase, lasting 3-6 weeks), destruction of follicles dumps stored hormone into circulation, producing symptoms of thyrotoxicosis: tremor, palpitations, anxiety, heat intolerance, and weight loss. Because the gland is being destroyed rather than stimulated, TSH is suppressed and RAIU is very low. This is the single most important concept separating destructive thyrotoxicosis from Graves disease.

In the second phase (hypothyroid phase, lasting weeks to months), the gland's hormone reserves are depleted and the damaged follicular cells cannot synthesize new hormone. TSH rises, and the patient may develop fatigue, weight gain, cold intolerance, and constipation.

In the third phase (recovery/euthyroid phase), follicular cells regenerate, hormone production normalizes, and the patient returns to a euthyroid state. Approximately 90-95% of patients recover full thyroid function, though a small subset develops permanent hypothyroidism.

The intense inflammatory infiltrate in the gland also explains the hallmark physical finding: a markedly tender thyroid. Granulomatous inflammation with multinucleated giant cells is the characteristic histologic pattern, which is why this condition is also called subacute granulomatous thyroiditis.

02Classification and Clinical Manifestation

Based on Phase

It is worth noting that not every patient passes through all three phases. Some patients present only in the thyrotoxic phase and recover directly without a clinically evident hypothyroid phase. The vignette will typically test phase 1 because this is where the diagnostic challenge lies.

Based on Type

03Diagnostic Workup

The clinical scenario of a patient with anterior neck pain, tenderness on palpation, and a recent viral illness combined with elevated ESR is often enough to raise strong suspicion. The thyroid function tests then confirm the phase.

The key diagnostic step that test-writers focus on is the RAIU. In Graves disease, the thyroid is overactive and avidly traps iodine, resulting in high RAIU. In subacute thyroiditis, the gland is being destroyed and is not trapping iodine at all, resulting in very low RAIU. Both conditions present with thyrotoxicosis (low TSH, high T4), but RAIU cleanly separates them. This is the most commonly tested distinction.

Thyroid ultrasound is supportive but not definitive. It typically shows poorly defined hypoechoic regions corresponding to areas of inflammation. FNA is almost never required unless there is diagnostic uncertainty or concern for malignancy (e.g., a dominant nodule in the setting of pain).

Anti-TPO antibodies help distinguish subacute thyroiditis from painless (silent) thyroiditis. In painless thyroiditis, anti-TPO antibodies are usually positive because the underlying mechanism is autoimmune. In subacute thyroiditis, they are typically absent or present at very low titers.

04Management and Treatment

Acute management centers on symptom control. The neck pain is the primary complaint, and NSAIDs are the first-line treatment for mild disease. If pain does not respond within 1-2 days or if the patient presents with severe symptoms (high fever, inability to swallow, debilitating pain), prednisone is the next best step. The response to glucocorticoids is typically dramatic and rapid, often within 24-48 hours. This brisk response is itself considered supportive of the diagnosis.

A common pitfall is the temptation to prescribe antithyroid drugs (methimazole, propylthiouracil). These drugs block new hormone synthesis, but in subacute thyroiditis, the thyrotoxicosis results from release of preformed hormone from damaged follicles, not from increased synthesis. Therefore, antithyroid drugs have no role in this condition. Beta-blockers alone are used to control adrenergic symptoms such as tachycardia, tremor, and anxiety.

During the hypothyroid phase, most patients are either asymptomatic or mildly symptomatic and do not require treatment. If symptoms are bothersome, a short course of low-dose levothyroxine can be given with the plan to discontinue after 6-8 weeks and recheck thyroid function. Permanent hypothyroidism occurs in roughly 5-10% of cases and requires lifelong levothyroxine.

Patients should be counseled that recurrence during glucocorticoid tapering is common (occurring in up to 20% of cases). This does not represent treatment failure; it simply requires extending the taper duration.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on subacute thyroiditis questions is by selecting antithyroid drugs for the thyrotoxic phase. The vignette will show a patient with classic thyrotoxicosis (low TSH, high T4, tremor, tachycardia), and methimazole will appear as an answer choice. The critical reasoning step is recognizing that destructive thyrotoxicosis from hormone spillage does not respond to drugs that inhibit hormone synthesis. The treatment is supportive: beta-blockers for symptoms and NSAIDs or glucocorticoids for pain.

The second major trap involves confusing subacute thyroiditis with Graves disease. Both produce thyrotoxicosis, but the discriminating features are pain and RAIU. A tender thyroid with low RAIU points to subacute thyroiditis. A nontender thyroid with high RAIU and possibly exophthalmos points to Graves disease. If the vignette describes a patient with thyrotoxicosis and does not mention pain, do not select subacute thyroiditis.

A subtler trap involves the hypothyroid phase. A vignette may describe a patient who had neck pain and thyrotoxicosis weeks ago and now presents with fatigue, weight gain, and elevated TSH. The test is checking whether you recognize this as the natural progression of subacute thyroiditis rather than new-onset Hashimoto disease. The history of a preceding painful thyrotoxic episode is the giveaway.

Finally, remember that the dramatic response to glucocorticoids is both a therapeutic and a diagnostic clue. If a patient with a painful thyroid and elevated ESR improves rapidly on prednisone, this strongly supports the diagnosis of subacute thyroiditis.